Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Next Previous
Trial Profile

A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 04 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab; Ciclosporin; Leflunomide; Methotrexate; Sulfasalazine
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms SPIRIT-H2H
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 15 Nov 2023 Results (n=354) of a post-hoc analysis assessing treatment effects of IXE and ADA at individual digit level among patients with PsA, nail PsO, and adjacent joint disease presented at the ACR Convergence 2023
  • 03 Jun 2023 Results of post hoc analysis comparatively assessing the effect of ixekizumab and adalimumab at the individual digit level in improving nail and joint disease, in patients with PsA and concomitant nail involvement, presented at the 24th Annual Congress of the European League Against Rheumatism
  • 21 Mar 2023 Results of post-hoc pooled analysis assessing patient-reported fatigue, using the SF-36 vitality domain, in patients who received ixekizumab 80 mg Q2W for 12 weeks for moderate-to-severe psoriasis across UNCOVER-1 (N=433), UNCOVER-2 (N=351), UNCOVER-3 (N=385), and IXORA-S (N=136) SPIRIT-H2H presented at the American Academy of Dermatology annual Meeting 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top